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B cellsRecently, we reported that PrPSc, a surrogate marker for prion disease, is associated with the cellular fraction
of blood from scrapie-infected sheep using a ligand-based immunoassay. In the study reported here, we
found that a subset of peripheral blood mononuclear cells is most likely to sequester PrPSc during both the
preclinical phase of disease and at clinical end point. These cells had a cell surface phenotype of MHC class II
DQ+, surface immunoglobulin+, CD11b+, CD11c+, CD21+/−, which is consistent with a subpopulation of B
cells. What role these cells play in the pathogenesis of scrapie is unclear, but they may contribute to the
trafﬁcking of prions to the spleen during early pathogenesis of the disease. Furthermore, tests for preclinical
diagnostics could be further improved by targeting these cells.
Crown Copyright © 2010 Published by Elsevier Inc. All rights reserved.Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases
are a group of fatal neurodegenerative disorders that include
Creutzfeldt–Jakob disease (CJD) and Kuru in humans, bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep and goats, and chronic
wasting disease (CWD) in deer. The causative agent is widely believed to
be a misfolded isoform of the normal, ubiquitously expressed cellular
protein, PrPc, which converts to the pathogenic form (PrPSc) and
accumulates largely in the central nervous system (Prusiner, 1998).
Prion diseases are associated with pathological changes in the
brain, which may include vacuolation, neuronal loss, astrocytosis, and
amyloid plaque formation. The period between infection and the
development of clinical signs is usually prolonged, and during this
period, there is often progressive accumulation of infectivity and PrPSc
in lymphoid tissue. While infection of the lymphoid tissue has no
apparent deleterious effects on the health of the affected individual, it
is likely to be a signiﬁcant reservoir of infectivity, which may be
spread through blood and blood products. Indeed, infectivity in blood
was recently demonstrated in both scrapie- and BSE-infected sheep
(Houston et al., 2000, 2008; Hunter et al., 2002) , in deer with CWD
(Mathiason et al., 2009), and in rodent models of prion disease
(Diringer, 1984; Gregori et al., 2006a,b; Gregori and Rohwer, 2007;
Holada et al., 2002; Manuelidis et al., 1978). In addition, blood.C. Edwards),
@vla.defra.gsi.gov.uk
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sion of vCJD to four human recipients (Hewitt, 2006; HPA, 2007;
Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006).
Currently, there is no widely available or validated live animal
blood test for prion diseases, possibly due to the anticipated low titre
of PrPSc in circulating blood (Brown et al., 2001). Nevertheless, using
protein misfolding cyclic ampliﬁcation (PMCA), PrPSc has been shown
to be associated with both the leucocyte and plasma fractions of the
blood in rodent models of disease (Castilla et al., 2005; Murayama
et al., 2007; Saa et al., 2006), and with the leucocyte fraction of blood
from scrapie-exposed sheep (Thorne and Terry, 2008). More recently,
we have described an immunoassay for the direct detection of PrPSc
associated with peripheral blood mononuclear cells (PBMC) during
both the preclinical and clinical phases of the disease (Terry et al.,
2009). The progressive increase in prions observed during the course
of disease is consistent with recently published transfusion studies
showing increased infectivity (Houston et al., 2008).
During scrapie infection, blood leucocytes are likely to be a key
player in the dissemination of prions during disease since they
recirculate through the lymphoreticular system (LRS). Furthermore,
PBMC from both scrapie-infected and uninfected sheep express
surface PrPc (Barclay et al., 2002; Halliday et al., 2005; Herrmann
et al., 2001), which is a requirement for prion infection (Brown et al.,
1999; Bueler et al., 1993; Kaeser et al., 2001). However, it is unclear
which leucocyte subset(s) is able to accumulate prions. Variation in
surface PrPc expression levels could modify a cell subset's ability to
accumulate or replicate the prion agent. For example, in sheep, CD4+
T lymphocytes express relatively low levels of surface PrPc (Rocchi
et al., 2007) while CD21-expressing lymphocytes show increased
levels of expression (Halliday et al., 2005).ghts reserved.
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prion disease, we have investigated the ability of different leucocyte
subsets in the blood of scrapie-exposed sheep to sequester PrPSc.
These studies will provide clues to the role of different leucocyte
subsets during disease pathogenesis and markers for more sensitive
diagnostic tests. Furthermore, in humans, these cells may represent
therapeutic targets.
Results
PrPSc is associated with MHC class II DQ-expressing cells in the blood
from sheep naturally infected with scrapie and experimentally infected
with BSE, during both the clinical and preclinical phases of the disease
Previous studies have implicated both B cells and cells of the
myeloid lineage, including conventional dendritic cells (DC), in the
dissemination of prions throughout the lymphoreticular system
(Aucouturier and Carnaud, 2002; Aucouturier et al., 2001; Brown,
1997; Flores-Langarica et al., 2009; Frigg et al., 1999; Huang et al.,
2002; Klein et al., 1997, 1998; Levavasseur et al., 2007; Mabbott et al.,
2001; Raymond et al., 2007; Sethi et al., 2007; von Poser-Klein et al.,
2008). To investigate this in more detail, we determined whether
PrPSc partitions with PBMC that express MHC class II DQ (MHC II DQ),
a marker constitutively expressed on both B cells and DC, from
scrapie- and BSE-infected sheep.
Subpopulations of PBMC distinguished by the expression of MHC II
DQ were separated from blood sampled from sheep naturally infected
with scrapie (n=11) or experimentally infected with BSE (n=2), all
showing clinical signs of disease at the time of sampling.Fig. 1. PrPSc is associatedwith PBMC expressingMHC II DQ from scrapie- and BSE-infected she
from VRQ/VRQ (n=7), and ARQ/VRQ (n=4) scrapie-infected sheep and ARQ/ARQ sheep i
fraction of MHC II DQ-concentrated (conc) and MHC II DQ-depleted (dep) and unseparate
comparedwith unseparated PBMC from scrapie-free sheep (-ve). (B) PrPScwas analysed from
(C) MHC II DQ-enriched fractions were analysed from blood sampled from VRQ/VRQ scrap
points during disease. Fractions contain equivalent cell numbers. Each column in A and B rep
standard deviation (SD). Statistical differences between the MHC II DQ fractions from infecte
sheep, the mean absorbency associated with the MHC II DQ unseparated (pb0.05) and the
free sheep.In VRQ/VRQ sheep, the assay signal observed in the MHC II DQ-
concentrated fraction was signiﬁcantly higher than the signal in either
the unseparated or depleted fraction and also when compared to the
negative controls (Fig. 1A). However, the signal observed in the MHC II
DQ-depleted fraction did not differ signiﬁcantly from the controls.
Collectively, these data indicate that PrPSc is speciﬁcally sequestered
withMHC II DQ-expressing cells in scrapie-infected VRQ/VRQ sheep. In
ARQ/VRQ sheep, a similar pattern of association was observed, and the
PrPSc signal was signiﬁcantly higher in the MHC II DQ-concentrated
fraction than in thedepleted fraction, althoughnosigniﬁcantdifferences
between cell fractions and the controls were found. Finally, a similar
trend was observed between cell fractions from BSE infected ARQ/ARQ
sheep, although again these differences were not found to be
signiﬁcantly different. It is possible that the lower signals obtained
and/or the fewer cases examined in these two genotypes contributed to
the inability to show a statistical difference between cell fractions and
the corresponding controls. Importantly, PrPSc was not detected in
eitherMHC II DQ-positive or -negative fractions from scrapie-free sheep
(Fig. 1B).
To determine whether PrPSc is also associated with MHC II DQ-
positive cells during the preclinical phase of disease, blood was
sampled monthly between 7 and 14 months of age inclusive
(equivalent to 2–17 months before the onset of clinical signs) from
ﬁve VRQ/VRQ scrapie-exposed sheep. Scrapie infection was con-
ﬁrmed in all ﬁve sheep by recto-anal mucosa-associated lymphoid
tissue (RAMALT) biopsy and immunohistochemistry at 14 months of
age (data not shown). We found that PrPSc was detected in the MHC II
DQ positive fraction in 3/5 sheep and was detected consistently at all
time points in two sheep (sheep 2 and 5) (Fig. 1C). Notably, ‘sheep 2’ep. (A) PBMC subsets separated on the basis of the expression ofMHC II DQwere isolated
nfected with BSE (n=2); all showed clinical signs of disease. The PrPSc content of each
d (unsep) PBMC from infected sheep were compared. Also, MHC II DQ fractions were
MHC II DQ separated fractions from the PBMC fromVRQ/VRQ scrapie-free sheep (n=5).
ie-exposed sheep (sheep 1–5) or scrapie-free sheep (neg (n=5)) at preclinical time
resents the mean absorbance values for the total sheep tested. Error bars represent +1
d sheep were determined by two-way ANOVA as shown in the ﬁgure. Also, in VRQ/VRQ
concentrated fraction (pb0.001) were signiﬁcantly different from PBMCs from scrapie-
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the ﬁrst sheep to show clinical signs of disease andwere subsequently
culled at 22 and 19 months, respectively. At the time of writing, the
remaining sheepwere all still alive. In addition, PrPSc was not detected
in the MHC II DQ-negative fraction of cells in any of the ﬁve sheep at
any time point analysed (results not shown). Collectively, these
results indicate that in those sheep where PrPSc can be detected in the
blood, PrPSc consistently partitions in MHC II DQ-expressing cells and
that this occurs in both clinical and preclinical sheep.
Increased PrP surface expression on MHC II DQ-expressing cells in
scrapie-exposed and scrapie-free sheep
PrPc expression is a requirement for PrPSc replication (Brown et al.,
1999; Kaeser et al., 2001) and mice devoid of PrPc are resistant to
prion disease (Bueler et al., 1993). Since PBMC subsets express
different levels of surface PrPc (Halliday et al., 2005), it is possible that
different cell subsets might vary in their ability to support PrPSc
infection. Surface PrP on MHC II DQ-positive and -negative cells was
therefore measured with a panel of anti-PrP antibodies and analysed
by ﬂow cytometry. Irrespective of disease status, themean ﬂuorescent
intensity (MFI) was greater on MHC II DQ-positive cells than on MHC
II DQ-negative cells across all epitopes investigated, indicating a
higher level of PrPc expression on MHC II DQ-expressing cells
(Fig. 2A). In scrapie-free sheep, this difference was also observed,
but to a lesser extent. Heterogeneity of antibody binding was also
observed, and core (Sha31) and octapeptide repeat (SAF32) epitopes
were highly expressed while antibody FH11, which labels a region
within the N-terminus, revealed lower levels of ﬂuorescence. Reduced
N-terminal labelling of the PrP protein was previously described by
others and is likely to reﬂect either PrP truncation (Thackray et al.,
2006) or masking of the epitope. Differences in PrP expression or
epitope exposure were not observed between infected and control
sheep; however, the high level of PrPc expressed on the cell surface
may be masking detection of PrPSc on scrapie-infected cells. WeFig. 2. Cell surface PrP expression is greater on MHC II DQ positive PBMC from both scrapie-in
sheep (n=7, 16 months old) and scrapie-free control animals (n=4, 14 months old), and t
and -negative cells (open bars) was determined using 2-colour ﬂow cytometry with ant
Statistically signiﬁcant differences are indicated as *pb0.05, **pb0.01, and ***pb0.001. (B) M
sheep were isolated and analysed for PrPSc by EIA at increasing cell number. Error bars reptherefore cannot discount the possibility that PrPSc is expressed on the
surface of MHC II DQ-positive cells.
To ensure that the observed increase in assay signal associated
with MHC II DQ positive cells is attributed to PrPSc rather than the
increased expression of PrPc, MHC II DQ positive cells from both
scrapie-exposed and control sheep were analysed with increasing cell
numbers (Fig. 2B). The signal in the assay increased proportionally
with increasing numbers of MHC II DQ cells from the scrapie-positive
sheep. Conversely, no increase in signal was observed with MHC II
DQ-positive cells from unexposed animals, even when 4 times more
MHC II DQ cells were applied to the assay than required to give a
signal from infected sheep. These data would therefore argue against
detection of PrPc expressed by PBMC. Furthermore, previous studies of
PBMC from over 100 unexposed sheep failed to detect signals above
background levels (Terry et al., 2009).
PrPSc is not associated with PBMC expressing CD2 or CD14 but is
sequestered with cells expressing surface immunoglobulin
MHC II DQ is expressed on all sheep B cells (Puri et al., 1985), but
expression is rare on T cells from the peripheral blood (Dutia et al.,
1993). MHC II DQ is also expressed on cells of the monocyte/
macrophage lineage. To deﬁne more precisely the cells associated
with PrPSc, we examined the expression of the MHC II DQmolecule on
CD2-positive T cells, CD14-positive monocytes, and surface immuno-
globulin (sIg)-positive B cells from scrapie-infected sheep (n=5)
using ﬂow cytometry. We also investigated the partitioning of PrPSc
with PBMC separated on the basis of expression of these lineage
markers.
As previously described in uninfected sheep, the majority of B cells
(96.1%±1.9%), but only a proportion of T cells (17.2%±3.8%) and
CD14 cells (32.4%±6.4%), express MHC II DQ (Fig. 3A). PrPSc analysis
of CD2 fractions from infected sheep showed a signiﬁcantly higher
signal in the unseparated and depleted fractions compared to CD2-
concentrated cells, suggesting that PrPSc partitions in the CD2-fected and uninfected sheep. (A) PBMCs were isolated from VRQ/VRQ scrapie-exposed
he mean ﬂuorescence intensity (MFI) of surface PrP on MHC II DQ-positive (ﬁlled bars)
i-PrP antibodies as indicated. Columns represent means of MFI for all sheep tested.
HC II DQ-positive cells from VRQ/VRQ scrapie-infected (n=2) and scrapie-free (n=4)
resent +1 SD.
Fig. 3. PrPSc is associated with B cells and not with monocytes or T cells. (A) Representative two-colour ﬂow cytometry proﬁles showing MHC II DQ coexpression with (i) anti-CD2 (T
cells), (ii) anti-CD14 (monocytes), and (iii) VPM8 (sIg). (B) PrPSc content of fractionated PBMC separated on the basis of (i) expression of CD2 from three scrapie-infected sheep (one
sheep was sampled during the preclinical phase), (ii) expression of CD14 from two VRQ/VRQ scrapie-infected sheep and one ARQ/ARQ animal, and (iii) expression of sIg (VPM8)
from six VRQ/VRQ scrapie-infected sheep. Columns show the mean absorbance of all sheep tested. Cell fractions from each sheep were analysed at equivalent cell numbers (cells/
well×106). For the CD14 fractions, the unseparated and depleted cell fractions were also analysed at higher cell numbers per well. Error bars represent +1 SD. Statistical differences
between the fractions from the infected sheep were determined by two-way ANOVA as shown in the ﬁgure. Also, the mean absorbency associated with the CD2-depleted fractions
(pb0.05) and the VPM8-unseparated (pb0.01), -depleted (pb0.05), and -concentrated (pb0.001) fractions was signiﬁcantly higher than PBMCs from scrapie-free sheep.
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fractionwas signiﬁcantly higher than that observed in the scrapie-free
controls (Fig. 3Bi). These data indicate that PrPSc does not accumulate
within peripheral blood T cells during scrapie infection, although we
cannot rule out the possibility that T cells, which express the γ/δ T-
cell receptor (but not CD2) (Mackay et al., 1989), might contain PrPSc.
Similarly, PrPSc was not detected in CD14-enriched cell fractions
(Fig. 3Bii). However, CD14 cells only constitute approximately 5% of
all PBMC in sheep blood, and therefore, isolation of CD14-positive
subsets from 108 PBMC yielded less than 3×106 CD14-positive cells.
To obtain a signal above background 107 cells/well are required and
therefore analysis of the CD14-enriched cells at matched cell numbers
with CD14-depleted and unseparated PBMC did not give positive
signals. However, when the number of CD14-depleted and unseparated
cells per well was increased, the CD14-negative fraction gave a signal
equal to or higher than the unseparated population of cells, indicating
that most PrPSc was contained within the CD14-negative population.
Furthermore, given that the CD14-enriched fractions (at 3×106 cells)
contain the equivalent number of CD14-positive cells expected to be
found in approximately 6×107 unseparated PBMC, it is unlikely that the
CD14-bearingmonocytes are associatedwith themajority of PrPSc in theblood. Nevertheless, given the difﬁculty of obtaining sufﬁcient cells to
analyse 107 cells per well, we cannot rule out the possibility that some
signal is contained within the CD14 population.
Signiﬁcantly higher levels of PrPSc were associated with the VPM8-
concentrated fraction relative to both VPM8-depleted fractions and
the negative controls (Fig. 3Biii). VPM8 is reactive with the sheep
immunoglobulin light chain, indicating a direct association of PrPSc
with B lymphocytes in the blood of scrapie-infected sheep. A
signiﬁcant difference was also observed between the signal in the
depleted fraction and the controls, and therefore, the possibility that
prions might sequester in an additional cell population, albeit at low
levels, cannot be ruled out.
PrPSc is associated with a subpopulation of B cells
Two subpopulations of B cells have been described in several
species (Herzenberg and Tung, 2006). In sheep, these cells are
distinguished by their expression of CD21 and CD62L or CD11b and
CD11c (Chevallier et al., 1998; Gupta et al., 1998; Young et al., 1997),
although it is unclear whether they represent exactly the same
functional subsets as the B1 and B2 B-cell subsets described in mice
114 J.C. Edwards et al. / Virology 405 (2010) 110–119(Herzenberg and Tung, 2006; Tung et al., 2006). By ﬂow cytometry,
we showed that the majority of sheep peripheral blood B cells express
CD11b (69.7%±5.9%), while 26.9% (±12.2%) express CD21. Further-
more, although these cell surface antigens largely delineate two
reciprocal B-cell populations, the data presented here indicate
coexpression of CD21 on approximately 12.9% (±5.2%) of CD11b-
positive cells (Fig. 4A). Subsequent analysis of CD11b-enriched cells
showed that the assay signal was signiﬁcantly higher than equivalent
unseparated or CD11b-depleted populations suggesting that PrPSc is
principally associated with CD11b-enriched fractions (Fig. 4B). How-
ever, the signal in all three fractions was found to be signiﬁcantly
higher than PBMCs from scrapie-free sheep, indicating that some
residual signal may also be present in CD11b-depleted cells. To
investigate this further, PBMCs were also separated based on the
expression of CD11c, a marker expressed on the majority of CD11b
cells (86.4%±3.7%, data not shown). Like CD11b, the signal in the
CD11c-enriched fractions was signiﬁcantly higher than seen in either
the depleted or the unseparated cells, suggesting that PrPSc is associated
with these fractions. Furthermore, the signal obtained in the CD11c-
depleted fraction was not signiﬁcantly different from that seen inFig. 4. PrPSc is associated with CD11b and CD11c B-cell subsets in sheep blood. (A) Represen
markers VPM8 (sIg) with CD11b and CD21 and CD11b coexpression with CD21. (B) PrPSc as
VRQ/VRQ and one ARQ/ARQ scrapie-infected sheep. (C) CD11c expression from the blood o
during the preclinical phase. Each column represents the mean absorbance value from all
Statistical differences between the fractions from the infected sheep were determined by tw
CD11b-unseparated (pb0.05), -depleted (pb0.05), and -concentrated fractions (pb0.01) an
from scrapie-free sheep. (D) Three-colour cytometric analysis of B cells gated for absence of B
analysed for expression of CD11c.scrapie-free sheep. (Fig. 4C). Taken together, these data indicate that
PrPSc is highly enriched in a fraction of B cells coexpressing both the
CD11b and CD11c cell surface antigens. Three-colour ﬂow cytometry
conﬁrmed that the majority of sIg/CD11b cells in blood from scrapie-
infected sheep coexpress CD11c (Fig. 4D).
Analysis of CD21-positive and -negative fractions showed variable
partitioning of PrPSc. In three sheep, the PrPSc signal in the CD21-
depleted and -concentrated fractions were similar, suggesting that
both fractions have accumulated similar levels of prions (Fig. 5i).
However, in a fourth sheep, themajority of PrPSc appeared to partition
in the CD21-concentrated fraction (Fig. 5ii), and in a ﬁfth sheep, all
cell-associated PrPSc was present in the CD21-depleted fraction
(Fig. 5iii). The variable outcome does not appear to be dependent
on the clinical status of the sheep since the two animals where PrPSc
was found in both CD21 fractions were reported to be clinical and
preclinical, respectively (Fig. 5i). Therefore, we conclude that PrPSc
does not appear to partition cleanly with either subset of B cells based
on CD21 expression. This appears to contradict the CD11b and CD11c
fractionation studies, although this may be explained by the observed
overlap of CD21 expression with the CD11b/CD11c-positive subset.tative two-colour ﬂow cytometry proﬁles showing coexpression of sheep B cell subset
sociated with subfractions of B cells based on CD11b expression from the blood of three
f three VRQ/VRQ and one ARQ/VRQ scrapie-infected sheep, one of which was sampled
sheep tested. Fractions contain equivalent cell numbers. Error bars represent +1 SD.
o-way ANOVA as shown in the ﬁgure. Also, the mean absorbency associated with the
d the CD11c-unseparated fractions (pb0.001) was signiﬁcantly higher than in PBMCs
-cell lineage markers (H) or gated for dual expression of sIg (VPM8) and CD11b (B) and
Fig. 5. PrPSc is not consistently associated with either the CD21 or CD62L positive or negative fractions of B cells. (A) PrPSc associated with subfractions of B cells based on CD21
expression (i) from three scrapie-infected VRQ/VRQ sheep, one sampled during the preclinical phase, (ii) from a single VRQ/VRQ scrapie-infected sheep, and (iii) from a VRQ/VRQ
scrapie-infected sheep sampled during the preclinical phase. (B) Representative two-colour ﬂow cytometry proﬁles showing coexpression of CD62L and CD21 and CD11b on PBMC
from a scrapie-infected sheep. (C) PrPSc association with B cells separated on the basis of the expression of CD62L (i) from three VRQ/VRQ scrapie-infected sheep (two samples
during the preclinical phase) and (ii) from a single VRQ/VRQ scrapie-infected sheep also sampled during the preclinical phase. For ﬁgures Ai, Aii, and Ci where multiple sheep were
examined, each column represents the mean absorbance value for total number of sheep tested, and error bars represent +1 SD. However, for ﬁgures Aiii and Cii where a single
sheep was analysed, error bars represent 1 SE and reﬂect the values obtained for replicate wells. Statistical differences between the fractions derived from several infected sheep
were determined by two-way ANOVA as shown in the ﬁgure. Also, the mean absorbency associated with the CD21-unseparated fraction was signiﬁcantly higher than in PBMCs from
scrapie free sheep (pb0.05).
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delineated by CD62L, a marker previously shown to be exclusively
expressed by CD21 B cells (Gupta et al., 1998). We conﬁrmed that a
proportion of CD21 B cells coexpress CD62L (45.7%±12.7%). We also
observed that CD62L is expressed on a proportion of CD11b cells
(14.42%±4.76%), although the majority of these cells is likely to be
monocytes, since CD14 monocytes coexpress CD11b and CD62L
(Bonneau et al., 2006). Moreover, CD11b B cells are predominantly
CD62L negative (Gupta et al., 1998) (Fig. 5). Analysis of the PrPSc
content of the CD62L cell fractions resulted in two different patterns
of reactivity, thus mirroring our observations following CD21
fractionation. In three of the four sheep, the result was clear: the
CD62L-concentrated cells did not harbour any detectable PrPSc, and all
reactivity was located in the depleted cell fraction (Fig. 5). However,
in one sheep, the reverse was observed: the signal was statistically
higher in the CD62L-concentrated fraction compared to controls,
while the depleted fraction remained PrPSc-negative (Fig. 5).Taken together, the data presented in this study suggest that the
majority of detectable PrPSc is associated with a subset of sIg
expressing cells in the blood that coexpress MHC II DQ, CD11b and
CD11c and also coexpress CD21 in some sheep. This phenotype is
consistent with a subset of B cells, although we cannot rule out that
other minor populations of cells sequester PrPsc, and this is under
current investigation.
Discussion
In this report, we show that PrPSc is principally associated with B
cells in the blood of sheep infected with scrapie. To our knowledge,
this is the ﬁrst report identifying a subset of blood leucocytes shown
to concentrate prions. Others have attempted similar studies in
human sporadic CJD and reported that PrPSc is not associated with
platelets, NK cells, CD8+ T cells, CD4+ T cells, B cells, monocytes, or
granulocytes from the blood (Choi et al., 2009). This may, however, be
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not been implicated in sources of infectivity in blood transfusions
(Hewitt, 2006) and has a different pattern of pathogenesis that often
excludes infectivity in the LRS. It is therefore possible that PrPSc is not
present in the blood of these patients. Furthermore, the number of
cells analysed were far fewer than we report in this study and may
have been insufﬁcient for detection.
Consistent with our previous work (Terry et al., 2009), we were
unable to detect PrPSc in the blood from all scrapie-infected sheep.
Two of the ﬁve sheep sampled in the MHC II DQ study were
consistently negative for PrPSc in the blood and PrPSc could not be
detected in all sheep at the clinical end stage of disease (data not
shown). However, preliminary data, resulting from the study
presented here, showed that in a proportion of sheep, PrPSc could
be detected in the blood of these ‘test negative’ animals following
enrichment of the appropriate fraction. Indeed, the percentage of
clinical sheep (of assorted genotypes) giving a positive signal
following enrichment of either MHC II DQ, VPM8, CD11b, or CD11c
increased from 57.1% to 71.4% (n=28). This has potential implica-
tions for the development of diagnostics, since targeting the positive
cell population for testing would increase the sensitivity of the assay.
However, some sheep remained PrPSc-negative in the blood despite B
cell enrichment. Likewise, transfusion studies in sheep have indicated
that infectivity is not present in the blood from all sheep, although
transmission rates increased from 33% to 80% with increasing
incubation period of the donor (Houston et al., 2008). To this end,
PrPSc and/or infectivity may not be present in all animals and at all
time points during infection. Furthermore, it is not known in this
study whether the PrPSc detected is synonymous with infectivity: an
issue which is currently under investigation.
In sheep, two subpopulations of B lymphocytes have been
described with apparent anatomical distributions and functional
characteristics that can be differentiated based on the expression of
CD11b and CD11c (Chevallier et al., 1998; Gupta et al., 1998), or CD21
and CD62L (Gupta et al., 1998; Young et al., 1997). In line with these
distinctions, we show a direct association of PrPSc in blood with the
CD11b/CD11c-expressing subset of B lymphocytes. However, we
observed variability in the partitioning of PrPSc in the corresponding
CD21 and CD62L populations—a ﬁnding that would indicate that the
delineation of subsets by these cell surfacemarkers is not as precise as
previously suggested. Indeed, others have reported that 70% of CD21
cells express CD62L (Young et al., 1997) which is signiﬁcantly higher
than our observation (45.7%). The reason for this discrepancy is
unclear although it may be related to disease status, the age of the
sheep or different cell processing regimes. Indeed, CD21 expression
decreases with age (Young et al., 1999) and leucocyte activation can
modify CD62-L expression (Munro et al., 1996).
Sheep CD11b/CD11c and CD21/CD62L B cells subsets have been
likened to murine B-1 and B-2 cells, respectively (Chevallier et al.,
1998). In mice, these cell lineages appear to perform distinct
functions: B-1 cells are a major source of natural IgM antibodies
responding primarily to self and repetitive antigen in a T-cell-
independent manner and are believed to form the ﬁrst line of defence
in an immune response (Herzenberg and Tung, 2006). These cells are
also restricted to speciﬁc anatomical locations, including the spleen
and the peritoneal cavity as well as the blood (Kearney, 2005). On the
other hand, B-2 cells, or conventional B cells, require T cells for
costimulation and differentiation into plasma cells or memory cells.
They also undergo afﬁnity maturation to increase receptor diversiﬁ-
cation further. Interestingly, mice in which the CD19 molecule has
been deleted and therefore have reduced numbers of B-1 cells
demonstrate a signiﬁcantly shorter incubation period following
peripheral challenge with prions compared to both wild type controls
and CD22−/− mice, which have reduced number of B-2 cells (von
Poser-Klein et al., 2008). While this observation was explained by the
reduced distance observed between follicular dendritic cells (FDC)and the neighbouring nerve ﬁbres of the peripheral nervous system, it
is tempting to speculate that murine B-1 cells might also accumulate
prions in the blood and, in their absence, may have a direct effect on
disease pathogenesis. PrPSc aggregates are likely candidates for
recognition by B-1 cells, which favourmultimeric antigenic sequences
(Herzenberg and Tung, 2006), and many studies have demonstrated
predominant IgM responses following repeated immunisation with
prions (Korth et al., 1997; Paramithiotis et al., 2003; Tayebi et al.,
2004). Others have also suggested that B cells might play a role in
disease pathogenesis (Frigg et al., 1999; Klein et al., 1997, 1998),
although it is still unclear whether this goes beyond the secretion of
lymphotoxin, which serves to facilitate the maturation of FDC.
In sheep naturally infected with scrapie, haematogenous dissem-
ination might explain the progressive appearance of prions in
peripheral lymphoid tissue during the course of the disease (Jeffrey
and Gonzalez, 2007). During scrapie infection, prions are ﬁrst
detected in the ileal Peyers Patches (iPP) in lambs as young as
2 months of age (Andreoletti et al., 2000), which is consistent with
uptake from the gastrointestinal tract following oral exposure.
Subsequently, prions accumulate in other gut-associated lymphoid
tissue and eventually spread to distant peripheral lymphoid tissue
(van Keulen et al., 2006). In young sheep, the iPP represent a major
site for B-cell production and infected B cells originating from this site
could transfer prion infectivity to other regions of the LRS. However,
CD11b cells and their murine B-1 cell equivalents are predominantly
distributed in the blood and marginal zone of the spleen (Chevallier
et al., 1998; Bazin et al., 1982), indicating that these cells are unlikely
to re-enter secondary lymphoid tissues. This is supported by their lack
of expression of the homing molecule CD62L (Gupta et al., 1998).
Nevertheless, lymphocytes lacking CD62L do migrate to the spleen
(Tang et al., 1998), suggesting that CD11b cells might be at least partly
responsible for the high infectivity levels in spleen during prion
disease in sheep (Andreoletti et al., 2000; van Keulen et al., 1996,
2006). Moreover, substantial accumulations of PrPSc have been
detected in the splenic marginal zone of sheep with scrapie (Sorby
et al., 2009), which is consistent with the localisation of CD11b B -1
type cells (Chevallier et al., 1998).
Several other studies have implicated the dendritic cell as a likely
candidate for sequestration and transport of PrPSc though the LRS
(Aucouturier et al., 2001; Flores-Langarica et al., 2009; Huang et al.,
2002; Luhr et al., 2002; Sethi et al., 2007). Indeed, our previous study
showed that the blood-borne prion-infected cells could be as few as
0.005–0.1% of total PBMC, which is consistent with the paucity of DC
in the blood (Freudenthal and Bhardwaj, 1990). However, most DCs
are retained in the lymph node, and their exit and return to the blood
is a rare event (Randolph et al., 2008). These rare cells have not been
isolated and characterised in sheep, and therefore, the markers they
are likely to express are unknown. However, DCs do express cell
surface molecules that overlap with those of other lineages, most
notably CD11c and CD11b, so we cannot rule out the possibility that
we have copuriﬁed blood DC in our fractions.
In summary, we have shown that B cells or a subpopulation of B
lymphocytes concentrates PrPSc in the blood of scrapie-infected
sheep. Whether they are important to disease progression has not
been elucidated, but these studies provide a starting point for further
investigation on the role of blood cells in disease pathogenesis in
sheep and prion diseases in other species.
Materials and methods
Animals
All animal procedures were approved by the Home Ofﬁce under
the Animals (Scientiﬁc Procedures) Act 1986. Peripheral blood was
collected by jugular venipuncture from scrapie-infected, BSE-infected,
and uninfected control sheep.
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the Veterinary Laboratories Agency scrapie ﬂock, which was estab-
lished in 1995 through the purchase of siblings and offspring of
various breeds and genotypes born to scrapie-infected dams from
breeding and commercial ﬂocks. The ﬁrst conﬁrmed case of scrapie to
a ﬂock-born sheep was in 1998. The breeding programme for this
ﬂock aims to ensure a continued population of fully susceptible
genotypes to maintain a high infection pressure. Currently, all sheep
born in the ﬂock and carrying the scrapie-susceptible VRQ/VRQ
genotype develop clinical disease aged between 16 months and
3.3 years. Similarly, all ARQ/VRQ sheep born in the ﬂock develop
clinical disease aged between 17 months and 4.1 years.
The majority of the assays described in this report was performed
on blood sampled from VRQ/VRQ (n=32) and ARQ/VRQ (n=6)
clinically affected sheep at post mortem, with mean age at death of
23 months (range 21–27 months) and 27 months (range 24–
32 months), respectively. Sheep sampled during the preclinical
phase are described in the text and summarised in Table 1. For
sheep with BSE, Romney or Suffolk females were orally challenged
with a pool of BSE inoculums, which had been created from the
brainstems of 20 histologically conﬁrmed clinical cases of BSE in
cattle. Blood from uninfected age- and genotype-matched disease-
free animals was obtained from a ﬂock that has been stocked with
animals originating from New Zealand and maintained free of TSE
disease by strict biosecurity control.
Isolation of PBMC from sheep blood and separation of cell subpopulations
Bloodwas collected by jugular venipuncture andmixed with EDTA
as the anticoagulant. Occasionally, animals showing clinical signs of
disease were sedated with sodium thiopentone according to Home
Ofﬁce guidelines before blood collection. For collection of blood at
post mortem, sheep were euthanised with 10 ml of somulose and the
blood obtained by exsanguination. Buffy coats were then isolated by
centrifugation at 1400×g at 20 °C for 50 minutes. The buffy coat was
diluted 1:3 with cell wash buffer (Dulbecco's phosphate-buffered
saline (PBS) containing 0.002% EDTA, 0.5% BSA, and 0.1% sodium
azide). All buffers were used at ambient temperature unless otherwise
stated. Twenty milliliters of the cell suspension was carefully layered
onto 10 ml of Nycoprep™ (1.077 g/ml; Axis-Shield PoC AS, Oslo) and
centrifuged at 600×g for 30 minutes at 20 °C without braking. The
PBMCs were then harvested from the upper interface and were gently
washed. To remove residual platelets, the cells were layered over a
second density gradient of OptiPrep™ (1.063 g/ml; Axis-Shield PoC
AS, Oslo), and again, the cells were gently washed. Finally, the pellet
was resuspended in 2 ml of ammonium chloride lysis buffer (155 mM
NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.2–7.4) for 1 minute, and
then up to 40 ml of wash buffer was added immediately. The cells
were then centrifuged at 240×g at 20 °C for 20 minutes.
For cell separation based on cell surface molecule expression,
1×108 PBMCs were incubated with prepared antibody in dilutionTable 1
VRQ/VRQ sheep sampled during the preclinical phase.
Sheep
ID
Age of sheep when sampled
(months)
Age at post mortem
For time course study
(MHC II DQ)
Other cell
fractions
A 22 (CD2) 23 culled due to secondary infection
B 7 to 14 16 (CD21) 19
C 21 (CD21) 23
D 7 to 14 16 (CD62L) Alive
E 14 (CD11C) 23
F 7 to 14 Alive
G 7 to 14 Alive
H 7 to 14 Alivebuffer (Dulbecco's PBS containing 1% BSA and 0.1% sodium azide) for
20 minutes at 4 °C. Unbound antibodywas removed by addition of cell
wash buffer and centrifugation at 240×g for 5 minutes. For cell
concentration, 200 µl of MACS magnetic beads conjugated to isotype-
matched secondary antibody (Miltenyi Biotech) were added and
incubated for 15 minutes at 4 °C. Following a second wash, the cells
were incubated with a second, isotype-matched secondary antibody
conjugated to phycoerythrin to assess the purity of the subsequent
unseparated, depleted (unlabelled), and concentrated (labelled) cell
fractions.
Cell separation was carried out according to the protocol detailed
for LS columns (Miltenyi Biotech). The unseparated, depleted, and
concentrated cells were counted and collected at equivalent cell
numbers. Cells were frozen at −80 °C before immunoassay for PrPSc.
The purity of each of the fractions was determined by ﬂow cytometry,
and the contamination was less than 5% in the depleted fraction, and
the purity was greater than 90% in the concentrated fraction.Antibodies and ﬂow cytometric analysis
Antibodies used for cell separations included anti-sheepMHC II DQ
monomorphic (38.27; Serotec) (Puri et al., 1985), CD2 (MUC2A;
VMRD inc.) (Mackay et al., 1989), VPM8 (sIg) (gift from Barbara
Blacklaws) (Yirrell et al., 1991), CD14 (Tük4; Acris Antibodies) (Gupta
et al., 1996), anti-bovine CD21 (CC21; Serotec) (Howard et al., 1991;
Naessens et al., 1990) anti-bovine CD11b (CC126; Serotec) (Howard
and Naessens, 1993; Naessens et al., 1993), anti-ovine CD11c (OM1;
Gift from Barbara Blacklaws with permission from Michel Olivier)
(Gupta et al., 1993), and anti-bovine CD62L (CC32; Serotec) (Sopp
and Howard, 2001). Anti-PrP antibodies used were FH11 (residues
54–57), SAF32 (octapeptide repeat 79–92), 6H4 (144–152), and
Sha31 (145–152).
For two-colour cytometric analysis PBMC were labelled with anti-
PrP antibodies or antibodies speciﬁc for cell surface markers as stated
(or normal mouse serum). To determine coexpression of surface
markers on PBMC populations, blood was taken from ﬁve scrapie-
exposed sheep approximately 17 months of age. To avoid using the
same antibody isotypes, anti-ovineMHC II (SW73.2; Acris Antibodies)
(Hopkins et al., 1986) and anti-CD11c (BAQ153A; VMRD Inc.)
(Howard et al., 1991) antibodies were included in this series of
experiments. Brieﬂy, the cell pellets containing 106 cells were gently
resuspended and incubated with antibody at 4 °C for 20 minutes.
Excess antibody was washed off, and labelling was detected by
incubation with anti-mouse isotype-matched secondary antibodies
conjugated to phycoerythrin (BD Pharmingen) and FITC (BD Phar-
mingen). The cells were ﬁnally washed and assessed for cell surface
labelling using 2-colour ﬂow cytometry (EPICS, Coulter).
Where the antibodies were of the same subclass, labelling was done
sequentially with a 30-minute blocking step using 5 mg/ml normal
mouse serum in PBS before probing the cells with the second antisubset
antibody and the isotype-matched, ﬂuorochrome-conjugated secondary
antibody. The labelling of the subset antibodies was also assessed by one-
colourﬂowcytometry to ensure that the two-colour protocol did not alter
results.
For three-colour ﬂow cytometric analysis, PBMCs were labelled
with VPM8 (sIg), anti-CD11b (CC126; Serotec), and anti-CD11c
(BAQ153A; VMRD Inc.), and labelling was detected by anti-mouse
isotype-matched secondary antibodies conjugated to FITC, PE, and
PerCP-Cy5.5, respectively. PBMCs were also analysed using single-
colour and two-colour ﬂow cytometry to ensure the three-colour
protocol did not alter the results.
Where indicated, percentages of subset positive cellswere calculated
by the percentage of dual positive cells/total number of subset of
interest positive cells. For example for the percentage of B cells that also
express MHC II DQ, the calculation would be 20/20.5×100% (as shown
118 J.C. Edwards et al. / Virology 405 (2010) 110–119in Fig. 3Aiii). The ﬁgures quoted in the text are means of ﬁve individual
sheep.
Immunoassay for the detection of PrPSc
The assay for the detection of PrPSc associated with PBMC has been
previously described (Terry et al., 2009) and is amodiﬁedprotocol of the
IDEXX HerdChek CWD antigen EIA. Brieﬂy, cell pellets were frozen,
thawed, and diluted inwater. Thawed cellswere ribolysed, homogenate
removed, and mixed with working plate diluent. Samples were then
analysed according to the manufacturer's instructions, except that the
plate was incubated for 2.5 hours with agitation at room temperature
and then washed six times with wash solution 1 (provided in the kit).
Absorbance was read at 450 nm and 620 nm using a Victor multiwell
plate reader (Perkin-Elmer). Depending on the number of cells
enriched, analysis of the fractions was single well, in duplicate or
triplicate. Cells from ﬁve uninfected genotype-matched sheep were
analysed simultaneously.
Statistical analysis
To determine statistically signiﬁcant differences between the
absorbance values for each of the cell fractions isolated from scrapie-
exposed sheep, a two-way analysis of variance (ANOVA)was usedwith
sheep and cell fractions as the main effects and the interaction as the
error term. Differences between each pair of fractions were determined
by t tests using the ANOVA error mean square. In addition, t tests
allowing for unequal variance were used to compare cell fractions with
PBMCs from scrapie-free sheep.
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